Impact Factor 5.511
2017 JCR, Clarivate Analytics 2018

Among the world's top 10 most-cited Immunology journals

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2019.00041

Regulation of antigen export to the cytosol during cross presentation

  • 1INSERM U932 Immunité et Cancer, France

Cross-priming refers to the induction of primary cytotoxic CD8+ T cell responses to antigens that are not expressed in the antigen presenting cells (APCs) that induce the priming (i.e responses to tumor antigens or to antigens from viruses that do no infect APCs). Cross-presentation names the process allowing uptake of antigens, their processing into peptides, and the subsequent loading and presentation of these peptides by Major Histocompatibility Complex (MHC) class I molecules. Despite extensive research efforts to understand the intracellular pathways underlying antigen cross-presentation, certain critical steps remain elusive and controversial. Here we review recent advances and general considerations about cross-presentation, focusing on the mechanisms involved in antigen export to the cytosol, a crucial step of this pathway.

Keywords: Dendritic Cells, cross-presentation, cytosolic antigen export, ERAD pathway, endosomal leakage

Received: 29 Sep 2018; Accepted: 09 Jan 2019.

Edited by:

Diana Dudziak, Hautklinik, Universitätsklinikum Erlangen, Germany

Reviewed by:

Margarita Del Val, Spanish National Research Council (CSIC), Spain
Marianne Boes, Utrecht University, Netherlands  

Copyright: © 2019 GROS and Amigorena. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Sebastian Amigorena, INSERM U932 Immunité et Cancer, Paris, France,